OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Thrombosis and Thrombolysis is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Characteristics and comparisons of acute stroke in “recovered" to “active COVID-19 and “pre-pandemic” in Qatar database	54
Limb ischemia due to spontaneous heparin-induced thrombocytopenia as the primary presentation of acute COVID-19 infection	40
Association of the careggi collateral score with radiological outcomes after thrombectomy for stroke with an occlusion of the middle cerebral artery	36
Trends in management and outcomes of pulmonary embolism with a multidisciplinary response team	32
Predictors of symptomatic intracranial hemorrhage after endovascular treatment for acute large vessel occlusion: data from ANGEL-ACT registry	29
Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians	27
Management of bone marrow biopsy related bleeding risks: a retrospective observational study	26
Variables associated with adequate INR reversal in warfarin treated patients receiving 4-factor prothrombin complex concentrate	25
Contact system activation in disseminated intravascular coagulation: activities of prekallikrein and high-molecular-weight kininogen are significant risk factors	23
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding	21
The pharmacokinetics of recombinant FXIII (catridecacog) from the MENTORTM2 trial to a real-world study: a head-to-head comparison	21
Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series	21
Evaluation of outcomes with apixaban use for venous thromboembolism in hospitalized patients with end-stage renal disease receiving renal replacement therapy	19
Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes	19
Long-term outcomes in acute coronary syndrome patients without standard modifiable risk factors: a multi-ethnic retrospective cohort study Of 5400 asian patients	17
Direct oral anticoagulants for the treatment of atrial fibrillation in patients with hematologic malignancies	16
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum	14
Thrombosis in VEXAS syndrome	14
Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: a systematic review and Bayesian network meta-analysis of randomized tri	14
Popliteal cysts are not a risk factor for lower extremity deep vein thrombosis	13
Metformin therapy in COVID-19: inhibition of NETosis	13
Forensic autopsy-confirmed thrombosis-related deaths: the danger in the bones	13
Real-world evidence of lupus anticoagulant testing: simultaneous positivity of diluted Russell’s viper venom time and silica clotting time increases thrombotic risk prediction	12
The use of colchicine as an anti-inflammatory agent for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis	12
Efficacy and safety of app-based remote warfarin management during COVID-19-related lockdown: a retrospective cohort study	11

Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature	11
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study	11
Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients	10
A comprehensive review of vascular complications in COVID-19	10
Time to consider neuroinflammation as a booster effect of cerebral venous sinus thrombosis in vaccine-induced immune thrombotic thrombocytopenia?	10
Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia	10
Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors	9
SARS-CoV-2 antibody research in patients with unprovoked pulmonary embolism in COVID-19 pandemic period	9
Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States	9
Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome	9
Major hemorrhage and mortality in COVID-19 patients on therapeutic anticoagulation for venous thromboembolism	9
Intravenous thrombolysis and endovascular thrombectomy for acute ischaemic stroke in patients with Moyamoya disease - a systematic review and meta-summary of case reports	8
Lipoprotein(a) levels and risk of adverse events after myocardial infarction in patients with and without diabetes	8
Recurrent hematuria and painful necrotic purpura induced by acquired Protein S deficiency associated with monoclonal immunoglobulin	8
A survey of internists’ recommendations for aspirin in older adults and barriers to evidence-based use	8
Barriers and motivators to national board certification as a certified anticoagulation care provider	8
Juvenile patients with the homozygous MTHFR C677T genotype develop ischemic stroke 5 years earlier than wild type	8
Thromboembolic events following mRNA vaccines for COVID 19: a case series	8
Activated clotting time in inpatient diagnostic and interventional settings	8
Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials	8
REPLY to “Association Between Plasmatic Oxidative Stress and Thrombosis in Primary Antiphospholipid Syndrome”	7
Utilization trends and outcomes of catheter-directed thrombolysis for pulmonary embolism in the US by race/ethnicity	7
Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism	7
Prevalence of recommended anticoagulation by guidelines preadmission and its impact on the incidence of acute myocardial infarction (AMI) and in-hospital outcomes after AMI in atrial fibrillation pati	7
Modelling the procoagulatory effect of Anastrozole relative to ERα and ERβ expression in breast cancer cells	7
Self-controlled assessment of thromboembolic event (TEE) risk following intravenous immune globulin (IGIV) in the U.S. (2006–2012)	7
Incremental cost of venous thromboembolism in trauma patients with contraindications to prophylactic anticoagulation: a prospective economic study	7
Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series	6
Anticoagulation strategies and clinical outcomes after bleeding events during anticoagulation therapy for venous thromboembolism in the practice-based Japanese registry	6
Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study—Reply to comment from Muzaffar et al.	6
Contemporary use of ventilation-perfusion imaging for pulmonary embolism diagnosis	6
Answer to “REPLY to Association between Plasmatic Oxidative Stress and Thrombosis in Primary Antiphospholipid Syndrome”	6
Association of acidosis with coagulopathy and transfusion requirements in liver transplantation	6
Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC–MS/MS	6
Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study	6